Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Similarities Provide Evidence Latitude, Temple Says; Diovan Example?

Executive Summary

Pharmacologic similarity between compounds gives FDA greater latitude in the amount and type of data required for approval, Office of Medical Policy Director Robert Temple indicated during an Aug. 3 interview with "The Pink Sheet.

You may also be interested in...



Class Effect “Moratorium” Proposed By Harvard’s Avorn; FDA Should “Grow Up”

FDA should be less reliant on potential class similarities in evaluating safety and efficacy, pharmacoepidemiologist Jerry Avorn (Harvard University) said

Class Effect “Moratorium” Proposed By Harvard’s Avorn; FDA Should “Grow Up”

FDA should be less reliant on potential class similarities in evaluating safety and efficacy, pharmacoepidemiologist Jerry Avorn (Harvard University) said

FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says

FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai

Related Content

Topics

UsernamePublicRestriction

Register

PS046194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel